Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Svetlana O, Doronina"'
Autor:
Robert P. Lyon, Peter D. Senter, Erica E. McKinney, Jessica K. Simmons, Michelle L. Ulrich, Ivan J. Stone, Martha E. Anderson, Jamie B. Miyamoto, Nicole M. Okeley, Svetlana O. Doronina, Joshua H. Hunter, Scott C. Jeffrey, Joseph Z. Hamilton, Patrick J. Burke
Hematology paramters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34c95636a4c8b62c90712d22da689577
https://doi.org/10.1158/1535-7163.22508644.v1
https://doi.org/10.1158/1535-7163.22508644.v1
Autor:
Svetlana O. Doronina, Peter D. Senter, Robert P. Lyon, Jessica K. Simmons, Cindy Balasubramanian, Nicole Stevens, Kim K. Emmerton, Marsha L. Mason, Jamie B. Miyamoto, Jamie A. Mitchell, Andrew B. Waight, Tim D. Bovee, Philip N. Moquist
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4df524670b0ec7bba662eb1af95d3ac8
https://doi.org/10.1158/1535-7163.22521751
https://doi.org/10.1158/1535-7163.22521751
Autor:
Scott C. Jeffrey, Ivan Stone, Jessica K. Simmons, Patrick J. Burke, Erica E. McKinney, Peter D. Senter, Svetlana O. Doronina, Jamie B. Miyamoto, Joseph Z. Hamilton, Michelle Ulrich, Martha Anderson, Robert P. Lyon, Nicole M. Okeley, Joshua H. Hunter
Publikováno v:
Molecular Cancer Therapeutics. 16:116-123
The emergence of antibody–drug conjugates (ADC), such as brentuximab vedotin and ado-trastuzumab emtansine, has led to increased efforts to identify new payloads and develop improved drug-linker technologies. Most antibody payloads impart significa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dee3e1a62bc6f431620fc40610ec5d5
https://doi.org/10.1158/1535-7163.mct-16-0343
https://doi.org/10.1158/1535-7163.mct-16-0343
Autor:
Peter D. Senter, Svetlana O. Doronina
Publikováno v:
Cytotoxic Payloads for Antibody – Drug Conjugates ISBN: 9781788010771
The auristatins are a synthetic-peptide-based drug class that inhibit tubulin polymerization and can display exceptionally high potency on a broad array of cancer cells. Consequently, a tremendous amount of research has been focused the design and ut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e179cd00688ba1137d8e0d61b5111bc
https://doi.org/10.1039/9781788012898-00073
https://doi.org/10.1039/9781788012898-00073
Autor:
Cindy Balasubramanian, Chris Leiske, Jocelyn R. Setter, Fu Li, Svetlana O. Doronina, Robert P. Lyon, Martha Anderson, Joshua H. Hunter, Tim D. Bovee, Steven Duniho, Peter D. Senter
Publikováno v:
Nature Biotechnology. 32:1059-1062
Many antibody-drug conjugates (ADCs) are unstable in vivo because they are formed from maleimide-containing components conjugated to reactive thiols. These thiosuccinimide linkages undergo two competing reactions in plasma: elimination of the maleimi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d2bff7e6de2e632bfd5a5567db6723
https://doi.org/10.1038/nbt.2968
https://doi.org/10.1038/nbt.2968
Autor:
Robert P. Lyon, Marsha Quick, Philip N. Moquist, Andrew B. Waight, Sarah Owen, Tim D. Bovee, Sharsti Sandall, Svetlana O. Doronina, Margo Zaval, Jamie A. Mitchell, Nicole Blesie, Peter D. Senter, Kim K. Emmerton
Publikováno v:
Cancer Research. 78:2803-2803
Auristatins are a class of clinically validated antimitotic agents utilized as payloads in antibody-drug conjugates (ADCs). Auristatins display many of the desirable properties necessary for ADC cytotoxins, such as low nanomolar potency, cell permeab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74dfb56287792bb70b6288ba623865d8
https://doi.org/10.1158/1538-7445.am2018-2803
https://doi.org/10.1158/1538-7445.am2018-2803
Autor:
Scott C. Jeffrey, Damon L. Meyer, Minh T. Nguyen, Svetlana O. Doronina, Jamie B. Andreyka, Peter D. Senter
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 16:358-362
Highly potent and novel derivatives of doxorubicin were linked to monoclonal antibodies (mAbs) for site-specific drug delivery. Drug linker 5 consisted of a dipeptide linker attached directly to the daunosamine nitrogen of the n-butyldiacetate doxoru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b3742d2cd81bd472cc777d8d18d093d
https://doi.org/10.1016/j.bmcl.2005.09.081
https://doi.org/10.1016/j.bmcl.2005.09.081
Autor:
Brian A. Mendelsohn, and Alan F. Wahl, Ezogelin Oflazoglu, Russell J. Sanderson, Brian E. Toki, Damon L. Meyer, Charles G. Cerveny, Stephen C. Alley, Roger F. Zabinski, Svetlana O. Doronina, Peter D. Senter, Tim D. Bovee
Publikováno v:
Bioconjugate Chemistry. 17:114-124
We have previously shown that antibody-drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro and in vivo activities against antigen positive tumor models. MMAF is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::397fcfeadaeb9ffdf49cc7ceecaceac8
https://doi.org/10.1021/bc0502917
https://doi.org/10.1021/bc0502917
Autor:
Russell J. Sanderson, Michelle A. Hering, Stephanie F. James, Michael M.C. Sun, Svetlana O. Doronina, Anthony W. Siadak, Peter D. Senter, Alan F. Wahl
Publikováno v:
Clinical Cancer Research. 11:843-852
Effective antibody-drug conjugates (ADC) combine high drug-linker stability in circulation and efficient intratumoral release of drug. Conjugation of monomethyl auristatin E (MMAE) to the anti-CD30 monoclonal antibody (mAb), cAC10, produced a selecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bec13f19ba43e444582eba88f397050f
https://doi.org/10.1158/1078-0432.843.11.2
https://doi.org/10.1158/1078-0432.843.11.2
Autor:
Svetlana O. Doronina, Bruce Mixan, Dana F. Chace, Che-Leung Law, Clay B. Siegall, Peter D. Senter, Joseph A. Francisco, Kristine A. Gordon, Alan F. Wahl, Charles G. Cerveny, Damon L. Meyer, Kerry Klussman
Publikováno v:
Clinical Cancer Research. 10:7842-7851
The anti-CD20 antibody rituximab is useful in the treatment of certain B-cell malignancies, most notably non-Hodgkin’s lymphoma. Its efficacy has been increased when used in combination with chemotherapy, yet anti-CD20 monoclonal antibodies (mAbs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::753e402e6ff7830ad7bffd8071235681
https://doi.org/10.1158/1078-0432.ccr-04-1028
https://doi.org/10.1158/1078-0432.ccr-04-1028